Imara reports full year 2021 financial results and business highlights

Completed enrollment in phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (imr-687); expect to report both interim datasets in first week of april 2022
ELVN Ratings Summary
ELVN Quant Ranking